CIP
HAE icon

Convergence Investment Partners’s Haemonetics HAE Stock Holding History

Convergence Investment Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22,200
Closed -$2.54M – 333
2018
Q3 		$2.54M Sell
22,200
-17,279
-44% -$1.79M 0.52% 60
2018
Q2 		$3.54M Buy
39,479
+21,587
+121% +$1.82M 0.49% 73
2018
Q1 		$1.31M Sell
17,892
-17,248
-49% -$1.18M 0.17% 201
2017
Q4 		$2.04M Sell
35,140
-190
-0.5% -$10K 0.27% 124
2017
Q3 		$1.58M Buy
35,330
+340
+1% +$14.1K 0.22% 174
2017
Q2 		$1.38M Buy
+34,990
New +$1.44M 0.2% 193

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Convergence Investment Partners's HAE Position: Q4 2018 in Review

Convergence Investment Partners sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 22,200 shares — an estimated $2.54M sold.

Convergence Investment Partners first reported a position in HAE in Q2 2017 and held it in 6 quarters. The position peaked at $3.54M in Q2 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

  • Convergence Investment Partners reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
  • Convergence Investment Partners sold 22,200 Haemonetics shares in Q4 2018, an estimated $2.54M.
  • Convergence Investment Partners first reported a position in Haemonetics in Q2 2017 and held it in 6 quarters.
  • Convergence Investment Partners's Haemonetics position peaked at $3.54M in Q2 2018.
  • 279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Convergence Investment Partners's 13F filing for Q4 2018, filed 13 Feb 2019.